Osiris CEO heads for the door; Ignyta raises $54M; Conatus snags orphan drug designation for liver treatment;

@FierceBiotech: Xencor Prices Initial Public Offering. Release | Follow @FierceBiotech

@JohnCFierce: Sanofi is touting U300 PhIII diabetes data. Important program for the co. Release (PDF) | Follow @JohnCFierce

@DamianFierce: Kinda disappointed Celgene couldn't get more arcane clauses into this OncoMed deal. Story | Follow @DamianFierce

@EmilyMFierce: Male contraceptive breakthrough: Australian, UK researchers collaborate on protein discovery. More | Follow @EmilyMFierce

> After 10 years at the helm, Osiris Therapeutics ($OSIR) CEO Randal Mills is stepping down "for personal reasons," the company said, to be replaced by current COO Lode Debrabandere. Story

The oncology biotech Ignyta says it has raised $54 million from private placements of its stock. The money is earmarked for RXDX-101, a tyrosine kinase inhibitor, as well as RXDX-102 and its Spark-1 to Spark-3 discovery programs. Ignyta in-licensed RXDX-101from Nerviano Medical Sciences. Ignyta did not disclose which firms invested in the company. Release

> Conatus Pharmaceuticals ($CNAT) picked up an FDA orphan drug designation for emricasan, a Phase II treatment designed to forestall cirrhosis and end-stage liver disease in transplant recipients. Release

> France's Stallergenes has inked a collaboration pact with ActoGeniX to develop new allergy therapies. Release

Medical Device News

@FierceMedDev: Volcano green-lights a $200M share buyback under M&A pressure. News | Follow @FierceMedDev

@MarkHFierce: Inogen joins a select group of med device companies that have filed IPO plans this year. Article | Follow @MarkHFierce

@MichaelGFierce: Check out @FierceBiotech's Top Women in Biotech 2013. More | Follow @MichaelGFierce

@GalenMoore: Xlumena brings in hedge fund Third Point for a $25M Series C aimed at FDA approval. Release | Follow @GalenMoore

> 23andMe pulls ads after FDA warning, but sales roll on. More

> Medtronic unveils a $14M surgical training facility in Florida. Item

Pharma News

@FiercePharma: FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole. Release | Follow @FiercePharma

@EricPFierce: Takeda tries on outsider for CEO. Forest tees up cuts. GSK's Witty heads to China. Read it in FiercePharma. More | Follow @EricPFierce

@CarlyHFierce: ICYMI in FierceBiomarkers: Protein C4d linked to higher mortality rates in lung cancer patients. Story | Follow @CarlyHFierce

> Pfizer keeps piling onto consumer health business. Story

> Sources: Bayer, others kicking tires on Novartis animal health business. Article

> Novo expects to keep pumping out growth in insulin market. More

Pharma Manufacturing News

> Irish plant shutdown move puts another Merck site on the block. More

> Wockhardt braces for lost sales after FDA bans its main plant. Story

> Gland Pharma targets U.S. injectables sector after securing $200M. Article

> India drops plans to limit foreign ownership of production capacity. News

> FDA outlines plans for new compounding pharmacy powers. Report

> Hedge fund ups the ante in game of chicken with McKesson. Item

Biotech Research News

> NIH announces $100M for new HIV research initiative. Story

> Key hep C protein revealed, paving the way for new vaccines. News

> Novartis team IDs new malaria target. Article

> NIH publishes first Alzheimer's genomics data for researchers. Report

> Male contraceptive breakthrough: Australian, UK researchers collaborate on protein discovery. More

> Study: Standardization needed for drug screening studies. Item

 

Suggested Articles

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.